Expertise Biosecurity, Global Health Security
Daniel Irowa-Omoregie, MD, MPH, MBA, serves as a Horizon Biosecurity Fellow on NTI’s Global Biological Policy and Programs (NTI | bio) team. In this role, he assess financial levers for reducing biological risks as advances in biotechnology and AI reshape the threat landscape, designing mechanisms across insurance, reinsurance and liability through which capital markets can absorbs risks that the market currently leaves unpriced.
Before his placement at NTI, he conducted independent research on financing medical countermeasures and modeling the cross-sector economic impacts of biological threats. His earlier career spans life sciences, medical devices and global health: commercial strategy in synthetic biology, early-stage biotech investment as a venture fellow, and data-gap research in the life sciences as a research fellow. In development consulting, he supported the improvement of vaccines access to zero-dose children in Nigeria.
His research connects clinical, commercial, and capital-markets perspectives on why biological risk reduction is starved of private capital, and what risk-pricing infrastructure, financing instruments, and ultimately a dedicated asset class could draw it in.
He earned his medical degree from Obafemi Awolowo University, Ile-Ife, Nigeria, and his MPH and MBA from Johns Hopkins University.